

**14<sup>th</sup> January**



**Joana Pimenta, MD, PhD**

Local Health Unit of Gaia and Espinho, Faculty of Medicine of the University of Porto, IPO Porto Research Center

**Thromboembolism in the Ambulatory oncology patient**

**12<sup>th</sup> February**



**Cláudia Martins, PhD**

Junior Postdoctoral Researcher at i3S (Nanomedicines & Translational Drug Delivery Group)

**Cross-Model Evaluation of Amino Acid-Guided Nanomedicine for Glioblastoma Targeting**

**13<sup>th</sup> March**



**Anita Sveen, PhD**

Group Leader, Computational Oncology, Institute for Cancer Research, Oslo University Hospital; Associate Professor, Institute for Clinical Medicine, University of Oslo.

**Tumor Heterogeneity of Progression and Treatment Response in Colorectal Cancer**

**8<sup>th</sup> April**



**Sara Guerreiro, PhD**

i3S (Biofabrication Group), CDRSP and Member of Medical Physics, Radiobiology & Radiation Protection Group IPO Porto

**Implantable electrospun nanofibers containing gold nanoparticles for radiotherapy of gastric tumours**

**13<sup>th</sup> May**



**Rita Canário, MD, PhD**

i3S (Cancer Metastasis Group); University of Porto, Porto, Portugal; School of Medicine – University of Minho, Braga, Portugal

**P- cadherin: a promising biomarker of epithelial-mesenchymal plasticity in tubo-ovarian carcinoma**

**17<sup>th</sup> June**



**Vera Constâncio, PhD**

Cancer Biology & Epigenetics Group, IPO Porto Research Center

**Decoding Prostate Cancer: A Multimodal Approach from Biology to Clinical Application**

----- **SUMMER BREAK** -----

**9<sup>th</sup> September**



**Andreia Miranda, PhD Student**

Experimental Pathology & Therapeutics Group, IPO Porto Research Center & Amsterdam University Medical Center

**Sugar-coated killers: How cancer glycans eliminate immune cells**

**14<sup>th</sup> October**



**Daniela Silva, MD, PhD**

Coordinator of the Virology and Molecular Biology Division of the Clinical Pathology Department at IPO Porto; Member of the Molecular Oncology & Viral Pathology Group at IPO Porto

**Flow Cytometry-Based Colistin Susceptibility Testing**

**11<sup>th</sup> November**



**Ana Raquel Soares, PhD**

Group Leader of tRNA Epitranscriptome and Disease group, iBiMED, Department of Medical Sciences, University of Aveiro

**The Epitranscriptome: Unraveling a New Layer of Gene Expression Regulation**

**9<sup>th</sup> December**



**Maria José Oliveira, PhD**

Group Leader of Tumour and Microenvironment Interactions, Principal Investigator, i3S; Visiting Associate Professor, ICBAS—Abel Salazar Institute of Biomedical Sciences, University of Porto

**Rewriting the tumor microenvironment to overcome Radioresistance**